Analysis of these studies indicated pregnant patients should be given heparin plus low-dose aspirin to prevent pregnancy morbidity. However, “I don’t feel this is a settled matter,” said Dr. Branch. He said treatment with a heparin agent (typically a low molecular weight heparin) for recurrent early miscarriage in a woman with low-titer antiphospholipid antibodies is costly, potentially harmful and may be ineffective.
PROMISSE & IMPACT Studies
Dr. Branch introduced the Predictors of Pregnancy Outcome: Biomarkers in Antiphospholipid Antibody Syndrome and Systemic Lupus Erythematosus (PROMISSE) study, which was designed to identify predictors of adverse pregnancy outcomes in patients with APS or mild to moderate and stable systemic lupus erythematosus.1
Most patients with APS received the conventional treatment of a heparin agent plus low-dose aspirin during the observed pregnancy. Despite this, 19% of patients experienced adverse pregnancy outcomes, such as premature delivery, hypertensive disorders and thrombocytopenia, and 4% experienced fetal death, indicating women with APS are at risk for pregnancy failure, even with the standard conventional treatment. Dr. Branch noted these findings underscore how critical it is to closely monitor both mother and fetus.| ← Previous | | | Next → | Single Page